|
Tumor Invasion, Metastasis and Angiogenesis (TIMA)
Program Leader: Kathy Green, PhD
Program Co-Leader: Carole LaBonne, PhD
Membership Roster:
Tumor Invasion, Metastasis and Angiogenesis (TIMA) Membership Roster
The Tumor Invasion, Metastasis, and Angiogenesis (TIMA) Program of the Robert H. Lurie Comprehensive Cancer Center is a well-established research program that remains focused on multidisciplinary basic and translational research. The TIMA Program includes both basic research and clinical scientists with the common goal of providing a more detailed understanding of the individual cellular and molecular processes that underlie metastatic disease. Kathy Green, PhD and Carole LaBonne, PhD, a developmental cell biologist are the Leaders of this interdepartmental program that includes 32 faculty from 11 departments and 3 schools. Between January 2001 and September 2006 there have been 344 cancer relevant publications from the current program members. Eighty-four (24%) of these publications represent intra-programmatic collaborations and 63 (18%) represent inter-programmatic collaborations. Total current cancer-relevant peer-reviewed funding is $8,654,549 (direct) with $2,198,208 (direct) from NCI and $6,456,341 (direct) from other peer-reviewed sources. Specific areas of research focus include the regulation of cell adhesion and adhesion receptor signaling, investigation of matrix assembly and proteolytic remodeling of the stromal microenvironment, elucidation of the mechanisms that control epithelial-mesenchymal transitions, cell motility, and invasiveness, and characterization of the mechanisms that regulate tumor angiogenesis. Program members are highly interactive both intra- and inter-programmatically, participating in a number of joint basic and translational research initiatives. As the vast majority of cancer patient mortality is attributable to metastatic disease, the overall objective of the TIMA program is to obtain a more detailed understanding of these fundamental processes, and to translate these findings into the clinical setting as novel diagnostic or therapeutic approaches for the inhibition of tumor metastasis and angiogenesis.
Previous Page |
